Business Wire

SFL - Third-Quarter 2020 Financial Information

15.10.2020 21:37:00 EEST | Business Wire | Press release

Share

Regulatory News:

SFL (Paris:FLY)

Rental income: €137.7m

Consolidated revenue by business segment (€000’s)

 

 

 

2020
(9 months)

2019
(9 months)

Rental income

137,667

149,070

o/w

Paris Central Business District

114,845

121,877

 

Paris Other

20,996

25,786

 

Western Crescent

1,826

1,407

Other revenue

0

0

Total consolidated revenue

137,667

149,070

Consolidated rental income for the first nine months of 2020 amounted to €137.7 million, down €11.4 million or 7.6% from the €149.1 million reported for the same period of 2019.

  • On a like-for-like basis (excluding changes in consolidation scope affecting period-on-period comparisons), rental income contracted by €3.5 million. The 2.6% decline was due to the effects of the Covid-19 crisis, which led to rent holidays being granted to tenants of retail units and the closure of the Edouard VII and #cloud.paris conference centres as well as the Indigo hotel. Excluding the effects relating to the conference centres, the Indigo hotel and the Edouard VII car park, representing a reduction of €4.6 million in top-line rental income and of €2.8 million in net rental income, the like-for-like change in the top-line was a positive €1.1 million (0.8%).
  • Rental income from units being redeveloped or renovated in the periods concerned was down by €4.7 million, due to the renovation of several floors that were vacated in late 2019 and early 2020, mainly in the 103 Grenelle and Edouard VII buildings.
  • Lastly, period-on-period comparisons were adversely affected by the €3.2 million in income received from various penalties in 2019.

The rent recovery rate for the second and third quarters of 2020 currently stands at a very satisfactory 96% overall, and at 100% for office units. Negotiations are currently in progress with the remaining tenants that are behind with their rent, and agreements are imminent in the vast majority of cases.

Business review

Despite the Covid-19 crisis, which triggered a 46% drop in the Paris region’s rental market volume over the first nine months of 2020, the Group signed leases on around 18,000 sq.m. during the period, including 10,000 sq.m. of office space, on very good terms. They included the pre-letting of 85% of the 83 Marceau building which is currently being redeveloped and will be delivered in the second half of 2021.

The new office leases were signed at an average nominal rent of €867 per sq.m., corresponding to an effective rent of €754 per sq.m. These prices attest to the Paris rental market’s resilience and the very high quality of the Group’s properties.

The physical occupancy rate for revenue-generating properties stood at 94.7% at 30 September 2020 compared with 97.4% at 31 December 2019. The remaining vacant units mainly comprise 5,700 sq.m. of newly renovated offices in the 103 Grenelle building which have recently been delivered and the Le Vaisseau building in Issy-les-Moulineaux. The EPRA Vacancy Rate was 4.7% at 30 September 2020 versus 1.6% at 31 December 2019.

No properties were purchased or sold during the first nine months of 2020.

Financing

As part of its active debt management strategy, in early September SFL launched a tender offer on its two notes issues maturing in November 2021 and November 2022. The €160.7 million worth of notes tendered to the offer were retired, allowing SFL to reduce its future average borrowing costs and extend the average maturity of its debt.

SFL’s consolidated net debt at 30 September 2020 amounted to €1,874 million, compared with €1,732 million at 31 December 2019, representing a loan-to-value ratio of 24.3% based on the portfolio’s appraisal value at 30 June 2020. The average cost of debt after hedging was 1.5% and the average maturity was 4.7 years. At end-September 2020, the interest coverage ratio stood at 5.2x.

In addition, SFL had €1,040 million in undrawn lines of credit at 30 September 2020.

Management of the Covid-19 health crisis

From the onset of the crisis, SFL took all necessary measures to limit the pandemic’s effects on its business and results:

  • All the office buildings remained open and available for use by tenants and the necessary health protection measures deployed in the buildings’ common areas were regularly updated to comply with successive government directives.
  • The conference centres (Edouard VII and #cloud.paris) and the Indigo hotel (Edouard VII) that were closed during lockdown were re-opened in July, despite the very sluggish business environment.
  • Government measures concerning very small businesses and small retail outlets were applied and tenant requests for help were managed on a case-by-case basis in order to provide them with the necessary support as far as possible, for example by allowing them to defer payment of their second quarter rent.
  • Property leasing activities continued, keeping a close watch on the rental market.
  • Agreements were signed with the general contractors working on the main redevelopment projects currently in progress.
  • The Group’s financial liquidity was strengthened.

To ensure business continuity while also protecting employees, all of SFL’s teams worked from home during the lockdown and no employees were furloughed. Since the lockdown was lifted, they have been gradually returning to the office while benefiting from flexible office/home working arrangements.

SFL has also contributed to the collective effort to fight the pandemic by donating €550,000 to the Fondation de France’s programmes in support of hospitals and health workers, medical research and assistance for vulnerable people.

About SFL

Leader in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.2 billion and is focused on the Central Business District of Paris (#cloud.paris, Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies in the consulting, media, digital, luxury, finance and insurance sectors. As France’s oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties.

Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA

S&P rating: BBB+ stable outlook

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SFL - Thomas Fareng - T +33 (0)1 42 97 27 00 - t.fareng@fonciere-lyonnaise.com
Evidence – Grégoire Silly – Phone: 06 99 10 78 99 – gregoire.silly@evidenceparis.fr
www.fonciere-lyonnaise.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye